title: RAM, an RGDS analog, exerts potent anti-melanoma effects in vitro and in vivo.
abstract: Peptides containing the RGD sequence are under continuous investigation given their ability to control cell adhesion and apoptosis. Since small peptides are quickly metabolized and degraded in vivo, developing analogs resistant to serum-induced degradation is a challenging task. RGD analogs developed so far are known as molecules mostly inhibiting cell adhesion; this feature may reduce cell proliferation and tumor development but may not induce regression of tumors or metastases already formed. In the current study, carried out in melanoma in vitro and in vivo models, we show that RAM, an RGD-non-peptide Analog-Molecule, strongly inhibits cells adhesion onto plastic, vitronectin, fibronectin, laminin and von Willebrand Factor while it does not inhibit cell adhesion onto collagen IV, similarly to the RGDS template peptide. It also strongly inhibits in vitro cell proliferation, migration and DNA-synthesis, increases melanoma cells apoptosis and reduces survivin expression. All such effects were observed in collagen IV seeded cells, therefore are most likely independent from the anti adhesive properties. Further, RAM is more stable than the template RGDS; in fact it maintains its anti-proliferation and anti-adhesion effects after long serum exposure while RGDS almost completely loses its effects upon serum exposure. In a mouse metastatic melanoma in vivo model, increasing doses of RAM significantly reduce up to about 80% lung metastases development, while comparable doses of RGDS are less potent. In conclusion these data show that RAM is a potent inhibitor of melanoma growth in vitro, strongly reduces melanoma metastases development in vivo and represents a novel candidate for further in vivo investigations in the cancer treatment field.
authors: Laboratorio Patologia Vascolare, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
authors: Maria Simona
authors: MS
authors: Aguzzi
authors: Daniela
authors: D
authors: D'Arcangelo
authors: Claudia
authors: C
authors: Giampietri
authors: Maurizio C
authors: MC
authors: Capogrossi
authors: Antonio
authors: A
authors: Facchiano
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009842:Oligopeptides / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D055550:Protein Stability / Q000187:drug effects
chemical_list: C492321:1-carbamoyl-2-carboxyethylamino-malonyl-arginyl-phenylalanyl-argininamide; D000970:Antineoplastic Agents; D009842:Oligopeptides; D003094:Collagen; C046617:arginyl-glycyl-aspartyl-serine